AI Article Synopsis

  • Activation of M1 muscarinic receptors involves both orthosteric and allosteric binding sites, and researchers used site-directed mutagenesis to identify key residues affecting their function.
  • Specific amino acids were found critical for the agonist activity of compounds like AC-42 and TBPB, while N-desmethylclozapine engaged a different binding site without relying on those same residues.
  • The study indicates that various structurally different allosteric agonists can interact with distinct regions of the M1 receptor, suggesting multiple pathways for receptor activation.

Article Abstract

Activation of M1 muscarinic receptors occurs through orthosteric and allosteric binding sites. To identify critical residues, site-directed mutagenesis and chimeric receptors were evaluated in functional calcium mobilization assays to compare orthosteric agonists, acetylcholine and xanomeline, M1 allosteric agonists AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine hydrogen chloride), TBPB (1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one), and the clozapine metabolite N-desmethylclozapine. A minimal epitope has been defined for AC-42 that comprises the first 45 amino acids, the third extracellular loop, and seventh transmembrane domain (Mol Pharmacol 61:1297-1302, 2002). Using chimeric M1 and M3 receptor constructs, the AC-42 minimal epitope has been extended to also include transmembrane II. Phe77 was identified as a critical residue for maintenance of AC-42 and TBPB agonist activity. In contrast, the functional activity of N-desmethylclozapine did not require Phe77. To further map the binding site of AC-42, TBPB, and N-desmethylclozapine, point mutations previously reported to affect activities of M1 orthosteric agonists and antagonists were studied. Docking into an M1 receptor homology model revealed that AC-42 and TBPB share a similar binding pocket adjacent to the orthosteric binding site at the opposite face of Trp101. In contrast, the activity of N-desmethylclozapine was generally unaffected by the point mutations studied, and the docking indicated that N-desmethylclozapine bound to a site distinct from AC-42 and TBPB overlapping with the orthosteric site. These results suggest that structurally diverse allosteric agonists AC-42, TBPB, and N-desmethylclozapine may interact with different subsets of residues, supporting the hypothesis that M1 receptor activation can occur through at least three different binding domains.

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.110.065771DOI Listing

Publication Analysis

Top Keywords

ac-42 tbpb
20
allosteric agonists
12
agonists ac-42
12
ac-42
9
site distinct
8
orthosteric site
8
orthosteric agonists
8
minimal epitope
8
activity n-desmethylclozapine
8
binding site
8

Similar Publications

Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Neurobiol Dis

January 2014

Division of Neuropathology, Department of Pathology, Microbiology and Immunology, Vanderbilt University, USA.

Article Synopsis
  • - The discovery of allosteric modulators for G protein-coupled receptors (GPCRs) offers a new approach for creating treatments for various central nervous system (CNS) disorders, moving beyond traditional methods that target orthosteric sites.
  • - Allosteric modulators can enhance (positive) or inhibit (negative) receptor responses, leading to greater selectivity for specific receptor subtypes compared to traditional ligands.
  • - Research indicates that these allosteric agents have potential applications in treating neurodegenerative diseases like Alzheimer's and Parkinson's, as well as psychiatric disorders such as anxiety and addiction, while potentially minimizing side effects.
View Article and Find Full Text PDF
Article Synopsis
  • Activation of M1 muscarinic receptors involves both orthosteric and allosteric binding sites, and researchers used site-directed mutagenesis to identify key residues affecting their function.
  • Specific amino acids were found critical for the agonist activity of compounds like AC-42 and TBPB, while N-desmethylclozapine engaged a different binding site without relying on those same residues.
  • The study indicates that various structurally different allosteric agonists can interact with distinct regions of the M1 receptor, suggesting multiple pathways for receptor activation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!